A two-vaccine regimen intended to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical trial published in the March 14th issue of the Journal of the American Medical Association. The investigational vaccines included Ad26.ZEBOV, developed by Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and MVA-BN-Filo, developed by Bavarian Nordic. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), supported the development and testing of the experimental vaccines, beginning with early non-clinical and manufacturing process development.
Both of the vaccines in the regimen use harmless viral vectors, or carriers, to deliver proteins of the Ebola virus, which prompt an immune response. Ad26.ZEBOV uses a modified adenovirus vector to express proteins from Zaire ebolavirus, which was the species responsible for the 2014-2015 outbreak in West Africa. MVA-BN-Filo uses a modified vaccinia virus Ankara vector to express proteins from various species of Ebola virus, as well as the related Marburg virus.
The Phase 1 trial enrolled healthy participants ages 18-50 years in the United Kingdom and was conducted by the Oxford Vaccine Group at the University of Oxford. Participants were selected randomly to receive either the two-vaccine regimen or placebo (saltwater injections). Previously reported initial results showed the two-vaccine regimen is safe, well-tolerated and induced immune responses in participants eight months after immunization.
Of the 75 participants who received the vaccine regimen, 64 remained in the study for a follow-up visit on day 360. No serious vaccine-associated adverse events were observed, and all 64 participants maintained antibodies to Ebola virus at day 360. The researchers note additional research is necessary to assess the durability of immunity beyond one year and the immune response to booster doses of vaccine.
R Winslow et al. Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year. JAMA DOI: 10.1001/jama.2016.20644 (2017).
NIAID Director Anthony S. Fauci, M.D., is available for interviews.
To schedule interviews, please contact Jennifer Routh, (301) 402-1663, firstname.lastname@example.org.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.